Merck’s Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy

All NewsJune 23, 2025

Merck’s Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent